Patients with Cushing’s Syndrome Have Increased Intimal Media Thickness at Different Vascular Levels: Comparison with a Population Matched for Similar Cardiovascular Risk Factors

Abstract

Cushing’s syndrome (CS) is associated with high cardiovascular risk. The aim of this study was to analyze intimal media thickness (IMT) in patients with CS and compare them with subjects matched for similar conventional and independent cardiovascular risk factors. Twenty eight patients with CS (mean age: 40.7 ± 2.5 y) and 28 subjects (mean age: 41.1 ± 14 y) matched for sex, age, smoking habit, body mass index, blood pressure levels, glucose and lipid metabolism were evaluated. IMT was measured at right and left common carotid (CC), carotid bulb (BC), aorta (Ao) and femoral (F) levels by B-echo-Doppler ultrasonography. Although parameters of cardiovascular risk factors did not differ statistically between patients and controls, IMT was significantly increased (right and left CC-IMT, p < 0.05; right and left BC-IMT, p < 0.01, Ao-IMT p < 0.05) and wall plaques were more common (14.2 % vs. 7.1 %) in patients. In CS patients, CC-IMT and F-IMT correlated positively and significantly with fasting glucose (right CC-IMT: r² = 0.37, p = 0.05; left CC-IMT: r² = 0.43, p = 0.02; right F-IMT: r² = 0.57; p < 0.01; left F-IMT: r² = 0.47, p = 0.01) and HOMA index (left CC-IMT: r² = 0.64, p < 0.01 and left F-IMT: r² = 0.48, p < 0.05). The CS patients’ waist-to-hip ratio (WHR) was evaluated and correlated positively and significantly with CC-IMT (right: r² = 0.53, p = 0.01 and left: r² = 0.44, p = 0.05). No correlation was found between IMT and cortisol levels, however. In conclusion, patients with CS have more severe atherosclerotic damage than a population matched for similar cardiovascular risk factors. Multiple events related to long-term cortisol effects on metabolism and at vascular and endothelial sites may increase the risk of cardiovascular damage in patients with CS.

Cushing’s syndrome - intimal media thickness

References

• 1 Aron D C, Flinding J W, Tyrrel J B. Cushing’s disease.  Endocrinol Metab Clin North Am. 1987;  16 705-730
• 2 Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A. Adrenal incidentaloma: a new cause of the metabolic syndrome?.  J Clin Endocrinol Metab. 2002;  87 998-1003
• 3 Findling J W, Raff H. Diagnosis and differential diagnosis of Cushing’s syndrome.  Endocrinol Metab Clin North Am. 2001;  30 729-747
• 4 Leibowitz G, Tsur A, Chayen S D, Salameh M, Raz I, Cerasi E, Gross D J. Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients.  Clin Endocrinol (Oxf). 1996;  44 717-722
• 5 Contreras L N, Cardoso E, Lozano M P, Pozzo J, Pagano P, Claus-Hermbeg H. Detección de sindrome de Cushing preclínico en pacientes con sobrepeso y diabetes mellitus tipo 2.  Medicina. 2000;  60 326-330
• 6 Etxabe J, Vazquez J A. Morbidity and mortality in Cushing’s disease: an epidemiological approach.  Clin Endocrinol (Oxf). 1994;  40 479-484
• 7 Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing’s syndrome.  Endocrinol Metab Clin N Am. 2005;  34 327-339
• 8 O'Leary D H, Polak J F, Kronmal R A, Savage P J, Borhani N O, Kittner S J, Tracy R, Gardin J M, Price T R, Furberg C D. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group.  Stroke. 1996;  Feb 27 224-231
• 9 Lekakis J P, Papamichael C M, Cimponeriu A T, Lekakis J P, Papamichael C M, Cimponeriu A T, Stamatelopoulos K S, Papaioannou T G, Kanakakis J, Alevizaki M K, Papapanagiotou A, Kalofoutis A T, Stamatelopoulos S F. Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis.  Am J Cardiol. 2000;  85 949-952
• 10 Faggiano A, Pivonello R, Spiezia S, De Martino M C, Filippella M G, Di Somma C, Lombardi G, Colao A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission.  J Clin Endocrinol Metab. 2003;  88 2527-2533
• 11 Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure.  J Clin Endocrinol Metab. 1999;  84 2664-2672
• 12 Chalmers J. WHO-ISH Hypertension Guidelines Committee 1999. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension.  J Hypertension. 1999;  17 151-185
• 13 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 2000;  28 412-419
• 14 Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.  Diabetes care. 1999;  22 818-822
• 15 Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging.  Circulation. 1986;  74 1399-1406
• 16 Barnett H J, Taylor D W, Eliasziw M, Fox A J, Ferguson G G, Haynes R B, Rankin R N, Clagett G P, Hachinski V C, Sacket D L, Thorpe K E, Meldrum H E, Spence J D. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators.  N Engl J Med. 1998;  339 1415-1425
• 17 RebuffeŽ-Scrive M, Lundholm K, Björntorp P. Glucocorticoid hormone binding to human adipose tissue.  Eur J Clin Invest. 1985;  15 267-271
• 18 Bujalska I J, Kumar S, Stewart P M. Does central obesity reflect “Cushing’s disease of the omentum”?.  Lancet. 1997;  349 1210-1213
• 19 Steinberg H O, Shaker H, Leaming R, Johnson A, Brechtel G, Baron A D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.  J Clin Invest. 1996;  97 2601-2610
• 20 Denis C V. Von Willebrand factor in vascular pathophysiology.  Pathologie Biologie. 2003;  51 395-396
• 21 Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B, Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma.  Exp Clin Endocrinol Diabetes. 2000;  108 294-298
• 22 Kirilov G, Tomova A, Dakovska L, Kumanov P h, Shinkov A, Alexandrov A S. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome.  European J Endocrinol. 2003;  149 549-553
• 23 Kelly J J, Mangos G, Williamson P M, Whitworth J A. Cortisol and hypertension.  Clin Exp Pharmacol Physiol. 1998;  25 (Suppl) S51-S56
• 24 Healey B. Endothelial cell dysfunction: an emerging endocrinopathy linked to coronary disease.  J Am Coll Cardiol. 1990;  16 357-358
• 25 Zacharieva S, Atanassova I, Nachev E, Orbetzova M, Kirilov G, Kalinov K, Shigarminova R. Markers of vascular function in hypertension due to Cushing’s syndrome.  Horm Metab Res. 2005;  37 36-39